Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 628

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

Open access
Benkert, Pascal, Meier, Stephanie, Schaedelin, Sabine, Manouchehrinia, Ali, Yaldizli, Özgür, Maceski, Aleksandra, Oechtering, Johanna, Achtnichts, Lutz, Conen, David, Derfuss, Tobias, Lalive, Patrice H, Mueller, Christian, Müller, Stefanie, Naegelin, Yvonne, Oksenberg, Jorge R, Pot, Caroline, Salmen, Anke, Willemse, Eline, Kockum, Ingrid, Blennow, Kaj, Zetterberg, Henrik, Gobbi, Claudio, Kappos, Ludwig, Wiendl, Heinz, Berger, Klaus, Sormani, Maria Pia, Granziera, Cristina, Piehl, Fredrik, Leppert, David, Kuhle, Jens, Aeschbacher, Stefanie, Barakovic, Muhamed, Buser, Andreas, Chan, Andrew, Disanto, Giulio, D'Souza, Marcus, Du Pasquier, Renaud, Findling, Oliver, Galbusera, Riccardo, Hrusovsky, Kevin, Khalil, Michael, Lorscheider, Johannes, Mathias, Amandine, Orleth, Annette, Radue, Ernst-Wilhelm, Rahmanzadeh, Reza, Sinnecker, Tim, Subramaniam, Suvitha, Vehoff, Jochen, Wellmann, Sven, Wuerfel, Jens, Zecca, Chiara·2022·The Lancet Neurology

Abstract

BACKGROUND Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease-modifying therapies. METHODS For derivation of a reference database of sNfL values, a control group was created, comprising participants with no evidence of CNS disease taking part in four cohort studies in Europe and North America. We modelled the distribution of sNfL concentrations in function of physiological age-related increase and BMI-dependent modulation, to derive percentile and Z score values from this reference database, via a generalised additive model for location, scale, and shape. We tested the reference database in participants with multiple sclerosis in the Swiss Multiple Sclerosis Cohort (SMSC). We compared the association of sNfL Z scores with clinical and MRI characteristics recorded longitudinally to ascertain their respective disease prognostic capacity. We validated these findings in an independent sample of individuals with multiple sclerosis who were followed up in the Swedish Multiple Sclerosis registry. FINDINGS We obtained 10 133 blood samples from 5390 people (median samples per patient 1 [IQR 1-2] in the control group). In the control group, sNfL concentrations rose exponentially with age and at a steeper increased rate after approximately 50 years of age. We obtained 7769 samples from 1313 people (median samples per person 6·0 [IQR 3·0-8·0]). In people with multiple sclerosis from the SMSC, sNfL percentiles and Z scores indicated a gradually increased risk for future acute (eg, relapse and lesion formation) and chronic (disability worsening) disease activity. A sNfL Z score above 1·5 was associated with an increased risk of future clinical or MRI disease activity in all people with multiple sclerosis (odds ratio 3·15, 95% CI 2·35-4·23; p<0·0001) and in people considered stable with no evidence of disease activity (2·66, 1·08-6·55; p=0·034). Increased Z scores outperformed absolute raw sNfL cutoff values for diagnostic accuracy. At the group level, the longitudinal course of sNfL Z score values in people with multiple sclerosis from the SMSC decreased to those seen in the control group with use of monoclonal antibodies (ie, alemtuzumab, natalizumab, ocrelizumab, and rituximab) and, to a lesser extent, oral therapies (ie, dimethyl fumarate, fingolimod, siponimod, and teriflunomide). However, longitudinal sNfL Z scores remained elevated with platform compounds (interferons and glatiramer acetate; p<0·0001 for the interaction term between treatment category and treatment duration). Results were fully supported in the validation cohort (n=4341) from the Swedish Multiple Sclerosis registry. INTERPRETATION The use of sNfL percentiles and Z scores allows for identification of individual people with multiple sclerosis at risk for a detrimental disease course and suboptimal therapy response beyond clinical and MRI measures, specifically in people with disease activity-free status. Additionally, sNfL might be used as an endpoint for comparing effectiveness across drug classes in pragmatic trials. FUNDING Swiss National Science Foundation, Progressive Multiple Sclerosis Alliance, Biogen, Celgene, Novartis, Roche.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(22)00009-6

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 628

Metadata

Authors
Benkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., Lalive, P. H., Mueller, C., Müller, S., Naegelin, Y., Oksenberg, J. R., Pot, C., Salmen, A., Willemse, E., Kockum, I., Blennow, K., Zetterberg, H., Gobbi, C., Kappos, L., Wiendl, H., Berger, K., Sormani, M. P., Granziera, C., Piehl, F., Leppert, D., Kuhle, J., Aeschbacher, S., Barakovic, M., Buser, A., Chan, A., Disanto, G., D'Souza, M., Du Pasquier, R., Findling, O., Galbusera, R., Hrusovsky, K., Khalil, M., Lorscheider, J., Mathias, A., Orleth, A., Radue, E.-W., Rahmanzadeh, R., Sinnecker, T., Subramaniam, S., Vehoff, J., Wellmann, S., Wuerfel, J., & Zecca, C.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2022-03
Volume
21
Issue
3
Pages
246-257
ISSN
1474-4422 (ISSN-L)
OpenAlex
W4213066095
Cited by
628
References
35
FWCI
70.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. https://app.cochat.ai/papers/10.1016/s1474-4422(22)00009-6
The paper
Benkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., Lalive, P. H., Mueller, C., Müller, S., Naegelin, Y., Oksenberg, J. R., Pot, C., Salmen, A., Willemse, E., Kockum, I., . . . Zecca, C. (2022). Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(22)00009-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.